Can metabolic biomarkers help clinicians stratify adverse outcome risk in COVID-19 patients?
As hospitals in many countries are filling up with coronavirus disease 2019 (COVID-19) patients, it has become a matter of great urgency to stratify the risk of critical disease and death in this group of patients.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a respiratory virus but the acute illness it causes is not confined to the lungs. Rather, many terminally ill patients with COVID-19 display severe disruption of metabolic processes throughout the body, with multi-organ damage caused by underlying vascular damage and a hypercoagulable profile.
A recent preprint research paper published on the